Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 222 (TMEM222) is a human protein encoded by the TMEM222 gene, also known as C1orf160, located on chromosome 1p36.11[1][3][4]. The protein contains 208 amino acids and features three predicted transmembrane domains as well as a domain of unknown function (DUF778)[1][3]. TMEM222 is highly conserved across various eukaryotic organisms and is widely expressed in human tissues, with highest levels in the brain and in mature glutamatergic neurons, suggesting a specific function in neuronal development or synaptic activity[1][3]. Disease relevance has recently emerged, as biallelic deleterious variants in TMEM222 have been shown to cause an autosomal recessive neurodevelopmental disorder characterized by intellectual disability, motor and speech delay, and variable behavioral and neurological phenotypes, but the precise molecular function is not yet elucidated[3][4]. There is currently no evidence that TMEM222 is a therapeutic target, biomarker, or directly interacts with drugs[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 222 (TMEM222).